Koifman Edward, Tanne David, Molshatzki Noa, Leibowitz Avshalom, Grossman Ehud
Department of Internal Medicine D and the Hypertension unit, The Chaim Sheba Medical Center , Tel-Hashomer , Israel.
Blood Press. 2014 Oct;23(5):262-9. doi: 10.3109/08037051.2013.876771. Epub 2014 Feb 3.
Recent guidelines recommended different approaches to hypertension therapy. Our aim was to evaluate trends in blood pressure (BP) management among patients admitted with acute stroke over the past decade.
The study population comprised 6279 consecutive patients, admitted with an acute stroke, and included in a national registry of three consecutive periods conducted during the years 2004-2010. We compared patients' characteristics and temporal trends of antihypertensive therapy utilization before hospital admission.
Among 4727 hypertensive patients, 3940 (83%) patients have taken antihypertensive drug therapy - 1430 (30.2%) a single agent, 1500 (31.7%) two agents and 1010 (21.4%) three or more antihypertensive agents. The most common class used was renin-angiotensin system (RAS) blockers (n = 2575; 54%) followed by beta-blockers (n = 2033; 43%). The same pattern was observed in patients treated with monotherapy. The use of RAS blockers and beta-blockers has increased over the years (p < 0.001 for both), whereas the use of diuretics decreased and the use of calcium antagonists remained stable. Among those who were treated with a single agent, the use of diuretics and calcium antagonists decreased and the use of RAS blockers increased, whereas the use of beta-blockers remained unchanged.
RAS blockers and beta-blockers are the most common antihypertensive agents used in Israel. Over time, the use of RAS blockers and beta-blockers has increased, whereas the use of diuretics decreased.
近期指南推荐了不同的高血压治疗方法。我们的目的是评估过去十年中急性卒中住院患者的血压管理趋势。
研究人群包括6279例连续收治的急性卒中患者,纳入了2004 - 2010年期间连续三个阶段的国家登记系统。我们比较了患者入院前的特征以及降压治疗的时间趋势。
在4727例高血压患者中,3940例(83%)接受了降压药物治疗——1430例(30.2%)使用单一药物,1500例(31.7%)使用两种药物,1010例(21.4%)使用三种或更多降压药物。最常用的药物类别是肾素 - 血管紧张素系统(RAS)阻滞剂(n = 2575;54%),其次是β受体阻滞剂(n = 2033;43%)。单药治疗的患者中也观察到相同模式。多年来,RAS阻滞剂和β受体阻滞剂的使用有所增加(两者p < 0.001),而利尿剂的使用减少,钙拮抗剂的使用保持稳定。在使用单一药物治疗的患者中,利尿剂和钙拮抗剂的使用减少,RAS阻滞剂的使用增加,而β受体阻滞剂的使用保持不变。
RAS阻滞剂和β受体阻滞剂是以色列最常用的降压药物。随着时间推移,RAS阻滞剂和β受体阻滞剂的使用增加,而利尿剂的使用减少。